PL3620171T3 - Przeciwciała anty-gm-csf i ich zastosowania - Google Patents

Przeciwciała anty-gm-csf i ich zastosowania

Info

Publication number
PL3620171T3
PL3620171T3 PL19180152.1T PL19180152T PL3620171T3 PL 3620171 T3 PL3620171 T3 PL 3620171T3 PL 19180152 T PL19180152 T PL 19180152T PL 3620171 T3 PL3620171 T3 PL 3620171T3
Authority
PL
Poland
Prior art keywords
applications
csf antibodies
csf
antibodies
Prior art date
Application number
PL19180152.1T
Other languages
English (en)
Inventor
Stefan Steidl
Elisabeth Thomassen-Wolf
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of PL3620171T3 publication Critical patent/PL3620171T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL19180152.1T 2005-05-18 2006-05-17 Przeciwciała anty-gm-csf i ich zastosowania PL3620171T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68200905P 2005-05-18 2005-05-18

Publications (1)

Publication Number Publication Date
PL3620171T3 true PL3620171T3 (pl) 2022-08-08

Family

ID=37114333

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06742970T PL1888643T3 (pl) 2005-05-18 2006-05-17 Przeciwciała przeciwko GM-CSF i ich zastosowania
PL19180152.1T PL3620171T3 (pl) 2005-05-18 2006-05-17 Przeciwciała anty-gm-csf i ich zastosowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL06742970T PL1888643T3 (pl) 2005-05-18 2006-05-17 Przeciwciała przeciwko GM-CSF i ich zastosowania

Country Status (26)

Country Link
US (5) US7867495B2 (pl)
EP (4) EP1888643B1 (pl)
JP (2) JP5295759B2 (pl)
KR (1) KR101308087B1 (pl)
CN (2) CN101218255B (pl)
AR (1) AR053608A1 (pl)
AU (1) AU2006249062B2 (pl)
BR (1) BRPI0610796B8 (pl)
CA (1) CA2608498C (pl)
CY (2) CY1115920T1 (pl)
DK (2) DK3620171T3 (pl)
ES (2) ES2527428T3 (pl)
HR (2) HRP20220755T3 (pl)
HU (1) HUE058876T2 (pl)
IL (1) IL187375A (pl)
LT (1) LT3620171T (pl)
ME (1) ME02059B (pl)
NO (1) NO344992B1 (pl)
NZ (1) NZ564027A (pl)
PL (2) PL1888643T3 (pl)
PT (2) PT3620171T (pl)
RS (2) RS63382B1 (pl)
RU (1) RU2447085C2 (pl)
SI (2) SI3620171T1 (pl)
TW (1) TWI477512B (pl)
WO (1) WO2006122797A2 (pl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013162B1 (ru) 2005-04-18 2010-02-26 Микромет Аг Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
EP1888643B1 (en) 2005-05-18 2014-10-29 MorphoSys AG Anti-gm-csf antibodies and uses therefor
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CN101501070B (zh) 2006-02-08 2013-12-25 诺福泰克公司 抗原性gm-csf肽和针对gm-csf的抗体
US20080171038A1 (en) * 2006-11-08 2008-07-17 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
SG176503A1 (en) 2006-11-21 2011-12-29 Kalobios Pharmaceuticals Inc Methods of treating chronic inflammatory diseases using a gm-csf antagonist
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
AU2008253608A1 (en) * 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009062238A1 (en) * 2007-11-12 2009-05-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
PT2215119E (pt) 2007-11-13 2013-02-11 Boehringer Ingelheim Int Anticorpos monoclonais que se ligam a hgm-csf e composições médicas que os compreendem
NZ585551A (en) 2007-11-26 2012-06-29 Bayer Schering Pharma Ag Anti-mesothelin antibodies and uses therefor
EP2088432A1 (en) * 2008-02-11 2009-08-12 MorphoSys AG Methods for identification of an antibody or a target
MX2010011761A (es) * 2008-04-28 2010-11-30 Kalobios Pharmaceuticals Inc Anticuerpos para el factor que estimula la colonia del granulocito-macrofago.
US8455623B2 (en) 2008-05-21 2013-06-04 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
KR20110044991A (ko) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＮＦ-α 길항제 다-표적 결합 단백질
CN108014335A (zh) 2008-12-22 2018-05-11 墨尔本大学 粒细胞巨噬细胞集落刺激因子的拮抗剂的用途
ES2886063T3 (es) 2008-12-22 2021-12-16 Univ Melbourne Tratamiento de la artrosis
SG175305A1 (en) * 2009-04-23 2011-11-28 Theraclone Sciences Inc Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
BRPI1006514A2 (pt) * 2009-05-05 2019-01-08 Morphosys Ag antagonista do gm-csf
AU2012280267B2 (en) * 2011-07-06 2016-04-21 Morphosys Ag Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
US9901079B2 (en) 2011-08-18 2018-02-27 New York University Inhibition of oncogenic kras-induced GM-CSF production and function
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
WO2013161814A1 (ja) 2012-04-23 2013-10-31 ジーンフロンティア株式会社 抗ヒトｃｄ６９抗体、及びその医薬用途
EP3540438A1 (en) 2012-08-17 2019-09-18 MorphoSys AG Complex-specific antibodies and antibody fragments and its use
KR20210021153A (ko) * 2012-09-20 2021-02-24 모르포시스 아게 류마티스 관절염에 대한 치료
KR20240091288A (ko) 2012-09-20 2024-06-21 모르포시스 아게 류마티스 관절염에 대한 치료
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
CA3126108A1 (en) 2012-11-09 2014-05-15 Genefrontier Corporation Anti-adam28 antibody for treating cancer
US20160024200A1 (en) * 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
AU2014314053C1 (en) 2013-08-30 2023-11-02 Takeda Pharmaceutical Company Limited Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
JP6202339B2 (ja) 2013-12-19 2017-09-27 国立研究開発法人国立精神・神経医療研究センター ＧＭ−ＣＳＦ産生Ｔ細胞制御剤、及びＴｈ１／Ｔｈ２免疫バランス調節剤
AU2015257798C1 (en) 2014-05-07 2020-10-22 Takeda Pharmaceutical Company Limited Liquid formulation comprising GM-CSF neutralizing compound
JP6490419B2 (ja) * 2014-12-24 2019-03-27 学校法人関西医科大学 制御性ｔ細胞分化誘導剤
GB201503139D0 (en) * 2015-02-25 2015-04-08 Univ Leicester Diagnostic and therapeutic target
EP3266799A4 (en) 2015-03-06 2018-09-12 GeneFrontier Corporation Anti-human membrane-type adam28 antibody
AU2017328383B2 (en) * 2016-09-19 2022-10-27 I-Mab Biopharma (Hangzhou) Co., Ltd. Anti-GM-CSF antibodies and uses thereof
CN107840886B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
CA3078349A1 (en) 2017-10-02 2019-04-11 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
WO2020078270A1 (en) 2018-10-15 2020-04-23 Elixiron Immunotherapeutics (hong Kong) Limited Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
JP7495403B2 (ja) 2018-11-09 2024-06-04 キニクサ ファーマシューティカルズ， リミテッド 巨細胞性動脈炎の治療
AU2020205951A1 (en) * 2019-01-07 2021-07-22 Hunan Siweikang Therapeutics Co. Ltd Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
CN114599398A (zh) 2019-06-03 2022-06-07 基尼克萨制药有限公司 用gm-csf拮抗剂治疗癌症
WO2021188409A1 (en) 2020-03-15 2021-09-23 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
KR20230095983A (ko) 2020-10-26 2023-06-29 키닉사 파마슈티컬스, 리미티드 Gm-csf 길항제를 사용한 암의 치료
NL2036015B1 (en) 2023-10-12 2025-04-30 Micronit Holding B V A method of manufacturing a nozzle assembly, comprising weakening a wafer at at least two focal zones in the depth direction by focusing a laser beam
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994009149A1 (en) * 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2060741A1 (en) 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
AUPP525198A0 (en) * 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
DE60041119D1 (de) 1999-07-20 2009-01-29 Morphosys Ag Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
WO2003068920A2 (en) * 2002-02-13 2003-08-21 Ludwig Institute For Cancer Research Humanized gm-csf antibodies
AU2003295576B2 (en) 2002-11-15 2011-03-17 Eisai, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
DE602004021773D1 (de) 2004-05-05 2009-08-13 Micromet Ag Herstellung eines einkettigen fv Antikörperfragments
EP1888643B1 (en) * 2005-05-18 2014-10-29 MorphoSys AG Anti-gm-csf antibodies and uses therefor

Also Published As

Publication number Publication date
US7867495B2 (en) 2011-01-11
EP1888643A2 (en) 2008-02-20
DK3620171T3 (da) 2022-06-07
AR053608A1 (es) 2007-05-09
US20090053213A1 (en) 2009-02-26
US20210347879A1 (en) 2021-11-11
TW200716674A (en) 2007-05-01
NZ564027A (en) 2011-06-30
PT1888643E (pt) 2015-01-14
JP5295759B2 (ja) 2013-09-18
HRP20150023T1 (hr) 2015-02-27
ES2527428T3 (es) 2015-01-23
CY1125427T1 (el) 2025-05-09
CN101218255B (zh) 2013-01-09
DK1888643T3 (en) 2015-01-05
CA2608498C (en) 2017-04-04
ME02059B (me) 2015-05-20
WO2006122797A3 (en) 2007-02-15
CN103087190B (zh) 2016-08-03
BRPI0610796B1 (pt) 2020-01-21
NO344992B1 (no) 2020-08-17
CN101218255A (zh) 2008-07-09
US9751939B2 (en) 2017-09-05
BRPI0610796A2 (pt) 2010-11-09
RU2447085C2 (ru) 2012-04-10
RS63382B1 (sr) 2022-08-31
TWI477512B (zh) 2015-03-21
EP2468773A2 (en) 2012-06-27
KR101308087B1 (ko) 2013-10-16
WO2006122797A2 (en) 2006-11-23
ES2918209T3 (es) 2022-07-14
RS53743B1 (sr) 2015-06-30
SI3620171T1 (sl) 2022-09-30
BRPI0610796B8 (pt) 2021-05-25
CN103087190A (zh) 2013-05-08
US11028165B2 (en) 2021-06-08
EP1888643B1 (en) 2014-10-29
HUE058876T2 (hu) 2022-09-28
PL1888643T3 (pl) 2015-04-30
RU2007147870A (ru) 2009-06-27
US20200024340A1 (en) 2020-01-23
NO20076437L (no) 2007-12-13
IL187375A (en) 2012-06-28
CY1115920T1 (el) 2017-01-25
HK1114620A1 (en) 2008-11-07
IL187375A0 (en) 2008-02-09
US20170218061A1 (en) 2017-08-03
LT3620171T (lt) 2022-06-10
SI1888643T1 (sl) 2015-03-31
EP3150221A1 (en) 2017-04-05
EP3620171B1 (en) 2022-04-20
EP3620171A1 (en) 2020-03-11
JP2013116912A (ja) 2013-06-13
WO2006122797B1 (en) 2007-04-19
HRP20220755T3 (hr) 2022-09-02
PT3620171T (pt) 2022-06-30
JP2008545632A (ja) 2008-12-18
CA2608498A1 (en) 2006-11-23
JP5769744B2 (ja) 2015-08-26
US20110045000A1 (en) 2011-02-24
EP2468773A3 (en) 2012-09-19
AU2006249062B2 (en) 2012-12-20
AU2006249062A1 (en) 2006-11-23
US10377820B2 (en) 2019-08-13
KR20080015008A (ko) 2008-02-15

Similar Documents

Publication Publication Date Title
PL3620171T3 (pl) Przeciwciała anty-gm-csf i ich zastosowania
HUS2100053I1 (hu) Interleukin-13-antitest-készítmény
PT1920065T (pt) Anticorpos anti-alfavbeta6 e suas utilizações
CY2019041I1 (el) Τροποποιημενα αντισωματα εναντι il-23
DK2059535T3 (da) Prlr-specifikt antistof og anvendelser deraf
DK1904104T3 (da) SP35-antistoffer og anvendelser heraf
DK1994055T3 (da) Anti-5t4-antistoffer og anvendelser deraf
NO20190202A1 (no) Anvendelse av anti-CGRP antagonist antistoff
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf
PT2993187T (pt) Anticorpos dirigidos para her-3 e suas utilizações
NO20076607L (no) TWEAK - bindende antistoff
LTPA2016026I1 (lt) Anti-il-17 antikūnai
HRP20150176T1 (xx) Protutijela protiv miostatina
DK1964852T3 (da) Anti-ilt7-antistof
PL2502938T3 (pl) Przeciwciała i immunokoniugaty oraz ich zastosowanie
NO20071430L (no) Anti-OX4OL antistoffer
DK2068887T3 (da) SP35-antistoffer og anvendelser heraf
IL204159A (en) Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
DK1971366T3 (da) Humane anti-IL-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
DK2907827T3 (da) Humaniserede anti-faktor D-antistoffer og anvendelser deraf
DK1599504T3 (da) Modificeret antistof
DE602006017373D1 (de) Madcam-antikörper
DE602005017080D1 (de) Toner und tonerherstellungsprozess
DK1979378T3 (da) Ny samling af HCDR3 områder og anvendelser derfor
PL1858481T3 (pl) Kompozycje oftalmologiczne i ich zastosowanie